Online ISSN: 1947-6027

Answering cancer’s most provocative questions

January 15, 2018
Cancer is a complex disease that often leaves scientists with more questions than answers. Therefore more creativity is needed to fully understand cancer. The National Cancer Institute’s Provocative Questions Initiative supports scientists who propose innovative strategies to address an unanswered question. The Origins of Cancer symposium held in July 2017 provided a platform for the scientific community to discuss unanswered and important questions in the field of cancer research. A summary of the symposium’s highlights was provided by the host institution, Van Andel Research Institute in Grand Rapids, MI, and appears in Genes & Cancer. Provocative Questions The Provocative Questions… continue reading »

Six genes implicated in aggressive triple-negative breast cancer

January 12, 2018
Researchers identified six genes that may be responsible for fueling the growth of an aggressive form of breast cancer called triple-negative breast cancer. The results of their study were published in Genes & Cancer. Triple-negative breast cancer Breast cancer is not one form of cancer, but many different subtypes. These subtypes of breast cancer are characterized by whether or not they possess the three proteins or “receptors” responsible for driving most breast cancers: estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). Cancers that test positive for any of the three can be treated successfully with hormonal… continue reading »

Genes & Cancer

Latest

What happens in colorectal cancer cells that resist treatment?

January 12, 2018
Researchers have learned more about what happens to colorectal cancer cells that cause them to resist treatment and fatally spread throughout the body. In an article published in Genes & Cancer, Dr. KayKay San and colleagues from Saint Louis University reported new insights that contribute to our understanding of the molecular mechanisms of resistance to chemotherapy, and specifically colorectal cancer and oxaliplatin resistance, and may one day allow researchers to reverse the process and, ultimately, improve chemotherapy outcomes. Previous studies have shown that cancer cells hijack a normal cell process called Epithelial-Mesenchymal Transition (EMT) in order to develop resistance to… continue reading »

Investigating a gene’s role in pancreatic cancer

January 10, 2018
A gene found to be triggered by exposure to environmental hazards is involved in the development and prognosis of pancreatic cancer, according to new research published in Genes & Cancer that explored a gene’s role in pancreatic cancer. The mineral dust-induced gene (mdig) is a cell growth-regulating gene that was first identified in patients with chronic lung diseases resulting from occupational exposure to mineral dust in mining industry. The gene can be induced by a number of environmental hazards, such as arsenic, silica, coal dust, and particulate matter. Pancreatic cancer and gene activation With very limited therapeutic options, pancreatic cancer… continue reading »

Interrupting the cell’s cycle may lead to a new treatment for a deadly mesothelioma

January 9, 2018
There may be a potential new treatment for a rare and aggressive form of tumor that affects the lining of internal organs known as malignant mesothelioma. Current treatment options have not proven to be very effective. In a review article published in Genes & Cancer, the authors pointed to drugs that inhibit a known mediator of cell cycle activity, cyclin dependent kinase 4 and 6 (CDK4/6), as being promising new treatments for mesothelioma based on the successful results of preclinical studies. In malignant mesothelioma cells, there is lower activity of the tumor suppressor gene CDKN2A. The researchers have learned that… continue reading »